Beta Bionics (NASDAQ:BBNX) CFO Sells $17,650.08 in Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 1,428 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $12.36, for a total value of $17,650.08. Following the completion of the sale, the chief financial officer owned 172,729 shares of the company’s stock, valued at $2,134,930.44. This represents a 0.82% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Stephen Feider also recently made the following trade(s):

• On Friday, January 2nd, Stephen Feider sold 20,000 shares of Beta Bionics stock. The stock was sold at an average price of $29.53, for a total value of $590,600.00.

Beta Bionics Price Performance

Shares of Beta Bionics stock traded down $0.95 during trading on Tuesday, hitting $11.57. 1,609,029 shares of the company were exchanged, compared to its average volume of 1,181,053. The firm’s fifty day moving average price is $18.74 and its 200 day moving average price is $22.43. Beta Bionics, Inc. has a 1-year low of $8.89 and a 1-year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.12. The business had revenue of $32.12 million for the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BBNX. UBS Group upgraded Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. Bank of America cut Beta Bionics from a “buy” rating to a “neutral” rating in a research note on Friday, January 9th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research note on Thursday, January 15th. Robert W. Baird lowered their price objective on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. Finally, Lake Street Capital set a $20.00 price objective on shares of Beta Bionics in a report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.20.

Hedge Funds Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Beta Bionics during the first quarter worth $95,000. Goldman Sachs Group Inc. purchased a new position in Beta Bionics in the 1st quarter worth $715,000. Woodline Partners LP acquired a new stake in shares of Beta Bionics during the first quarter worth about $1,530,000. Strs Ohio purchased a new stake in Beta Bionics in the first quarter valued at $29,000. Finally, Rhumbline Advisers purchased a new position in Beta Bionics during the first quarter valued at approximately $158,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.